Form 4 · Filed Mar 5, 2026, 12:00 PM UTC
EBS/Emergent BioSolutions Inc.
LINDAHL RICHARD S — EVP, Chief Financial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | F | other | 23,650 | $8 | $199,606 | 215,367 |
| Mar 3, 2026 | A | other | 72,856 | $0 | — | 557,346 |
Source: SEC EDGAR raw filing ↗ · Accession 0001196632-26-000009